Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.
Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Florida, Gainesville, Florida, United States.
Thromb Haemost. 2023 Jul;123(7):714-722. doi: 10.1055/a-2052-9381. Epub 2023 Mar 13.
The aim of this study was to identify the role of factor VIII (FVIII) in portal vein thrombosis (PVT) occurrence in cirrhotic patients with gastroesophageal variceal bleeding.
A total of 453 cirrhotic patients with gastroesophageal varices were enrolled. Computed tomography was performed at baseline and patients were divided into PVT and non-PVT groups ( = 131 vs. 322). Individuals without PVT at baseline were followed up for the development of PVT. Time-dependent receiver operating characteristic analysis of FVIII for PVT development was performed. The Kaplan-Meier methodology was used to analyze the predictive ability of FVIII for PVT incidence at 1 year.
FVIII activity (177.00 vs. 153.70, = 0.001) was significantly increased in the PVT group compared with the non-PVT group in cirrhotic patients with gastroesophageal varices. FVIII activity was positively correlated with the severity of PVT (161.50 vs. 171.07 vs. 187.05%, = 0.001). Furthermore, FVIII activity (hazard ratio [HR]: 3.48, 95% confidence interval [CI]: 1.14-10.68, = 0.029 in model 1; HR: 3.29, 95% CI: 1.03-10.51, = 0.045 in model 2) was an independent risk factor of 1-year PVT development in patients without PVT at baseline, which was confirmed by two separate Cox regression analysis and competing risk models. Patients with elevated FVIII activity exhibit a higher incidence of PVT in the non-PVT group at 1 year (15.17 vs. 3.16%, < 0.001). The predictive value of FVIII remains significant in individuals who have never received splenectomy (14.76 vs. 3.04%, = 0.002).
Elevated FVIII activity was potentially associated with the occurrence and the severity of PVT. It might be helpful to identify cirrhotic patients at risk of PVT.
本研究旨在确定凝血因子 VIII(FVIII)在肝硬化合并食管胃静脉曲张出血患者门静脉血栓形成(PVT)发生中的作用。
共纳入 453 例肝硬化合并食管胃静脉曲张患者。基线时行计算机断层扫描,患者分为 PVT 组和非 PVT 组(131 例与 322 例)。基线时无 PVT 的患者进行 PVT 发展的随访。对 FVIII 用于 PVT 发展的时间依赖性接受者操作特征分析。Kaplan-Meier 方法用于分析 FVIII 对 1 年 PVT 发生率的预测能力。
与非 PVT 组相比,肝硬化合并食管胃静脉曲张患者的 PVT 组 FVIII 活性(177.00 与 153.70, = 0.001)显著增加。FVIII 活性与 PVT 的严重程度呈正相关(161.50 与 171.07 与 187.05%, = 0.001)。此外,FVIII 活性(危险比 [HR]:3.48,95%置信区间 [CI]:1.14-10.68, = 0.029 模型 1;HR:3.29,95% CI:1.03-10.51, = 0.045 模型 2)是基线时无 PVT 的患者 1 年 PVT 发展的独立危险因素,这通过两次单独的 Cox 回归分析和竞争风险模型得到了证实。FVIII 活性升高的患者在非 PVT 组中 1 年内的 PVT 发生率更高(15.17 与 3.16%, < 0.001)。在从未接受脾切除术的个体中,FVIII 的预测价值仍然显著(14.76 与 3.04%, = 0.002)。
FVIII 活性升高可能与 PVT 的发生和严重程度有关。它可能有助于识别发生 PVT 的肝硬化患者的风险。